SNPHF (Santen Pharmaceutical Co) Growth Rank: 6 (As of Aug. 17, 2026) — 14% Below Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SNPHF Santen Pharmaceutical Co Ltd SNPHF
72 GF Score
Price $13.05
GF Value $10.45
Valuation Modestly Overvalued
View Full Analysis

What is Santen Pharmaceutical Co Growth Rank?

Santen Pharmaceutical Co SNPHF +4.40% 72 Growth Rank is 6 as of Aug. 17, 2026, which is 14% below its 10-year median of 7.00. GuruFocus rates SNPHF with a GF Score™ of 72/100 and a GF Value™ of $10.45 (Modestly Overvalued).

Santen Pharmaceutical Co has the Growth Rank of 6.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability, rated on a scale from 1 to 10. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

A higher score reflects a greater ability to drive business growth, with companies considered to have strong and sustainable expansion potential. Conversely, a lower score indicates challenges in achieving consistent growth and scalability.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

Santen Pharmaceutical Co Growth Rank Related Terms

SNPHF vs LLY, JNJ, ABBV: Growth Rank Comparison

For the Drug Manufacturers - General subindustry, Santen Pharmaceutical Co's Growth Rank, along with its competitors' market caps and Growth Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Santen Pharmaceutical Co Growth Rank vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Santen Pharmaceutical Co's Growth Rank distribution charts can be found below:

* The bar in red indicates where Santen Pharmaceutical Co's Growth Rank falls into.


SNPHF
72GF Score
Santen Pharmaceutical Co Ltd SNPHF
Growth Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Growth Rank →
What does a Growth Rank of 6 mean?
Santen Pharmaceutical Co (SNPHF) has a Growth Rank of 6 as of Aug. 17, 2026. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on Santen Pharmaceutical Co and its competitors. This is 14% below median its historical median of 7.00. Over the past decade, Santen Pharmaceutical Co's Growth Rank has ranged from 2.00 to 10.00.
Is Santen Pharmaceutical Co's Growth Rank too high?
Santen Pharmaceutical Co's current Growth Rank of 6 is 14% below median its 10-year median of 7.00. Over the past 10 years, this metric has ranged from a low of 2.00 to a high of 10.00. Overall, Santen Pharmaceutical Co has a GF Score™ of 72/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Santen Pharmaceutical Co's Growth Rank compare to LLY and JNJ?
Santen Pharmaceutical Co's Growth Rank of 6 can be compared against companies in the Drug Manufacturers industry. Historically, Santen Pharmaceutical Co's own Growth Rank has ranged from 2.00 to 10.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Growth Rank for a Drug Manufacturers company?
A good Growth Rank depends on the Drug Manufacturers industry context. However, Growth Rank should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Growth Rank mean?
A high Growth Rank can signal that a stock is expensive relative to its fundamentals. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on Santen Pharmaceutical Co and its competitors. Santen Pharmaceutical Co's current Growth Rank is 6, which is 14% below median its own 10-year median of 7.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Santen Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Santen Pharmaceutical Co (SNPHF) is currently considered Modestly Overvalued. The stock's GF Value™ is $10.45, compared to a current price of $13.05 — trading 24.9% above its estimated fair value. The current Growth Rank is 6, which is 14% below median its 10-year median of 7.00. Santen Pharmaceutical Co's overall GF Score™ is 72/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Growth Rank calculated?
Growth Rank is calculated from a company's financial statements. For Santen Pharmaceutical Co (SNPHF), the current Growth Rank is 6 as of Aug. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Santen Pharmaceutical Co (SNPHF) Overvalued in 2026?

Based on GuruFocus' analysis, Santen Pharmaceutical Co stock appears to be overvalued. The current stock price of $13.05 is trading 24.9% above its estimated GF Value™ of $10.45. GuruFocus considers Santen Pharmaceutical Co to be Modestly Overvalued.

Key valuation signals for SNPHF:

  • Growth Rank: 6 (14% below median its 10-year median of 7.00)
  • GF Value™: $10.45 vs. price of $13.05 (24.9% above fair value)
  • GF Score™: 72/100

No single metric tells the full story. See the SNPHF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Santen Pharmaceutical Co Business Description

Other Exchanges SNPHY:USA4536:Japan
Address 4-20 Ofukacho, Grand Front Osaka Tower A, Kita-ku, Osaka Prefecture, Osaka, JPN, 530-8552
Santen Pharmaceutical Co Ltd is a drug manufacturing company that focuses on ophthalmic products. The company provides a wide range of prescription and over-the-counter eye care products, including treatments for glaucoma, dry eye, and allergies. It also develops surgical and diagnostic devices related to eye care.
72GF Score

Get the complete analysis for SNPHF

Growth Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$13.05
Price
$10.45
GF Value